The success of clinical trials of selective B‐cell depletion in patients with relapsing multiple
sclerosis (MS) and primary progressive MS has led to a conceptual shift in the …

Age-associated B cells (ABCs) are a transcriptionally and functionally unique B cell
population. In addition to arising with age and following infection, ABCs are expanded …

Systemic lupus erythematosus (SLE) is a life-threatening autoimmune disease characterized
by adaptive immune system activation, formation of double-stranded DNA autoantibodies …

Patients diagnosed with B-cell non-Hodgkin lymphoma (B-NHL), particularly if recently
treated with anti-CD20 antibodies, are at risk of severe COVID-19 disease. Because studies …

Rationale: Systemic sclerosis (SSc)–pulmonary arterial hypertension (PAH) is one of the
most prevalent and deadly forms of PAH. B cells may contribute to SSc pathogenesis …

Signals controlling the generation of regulatory B (Breg) cells remain ill-defined. Here we
report an" auto"-regulatory feedback mechanism between plasmacytoid dendritic cells …

A small proportion of multiple sclerosis (MS) patients develop new disease activity soon after
starting anti-CD20 therapy. This activity does not recur with further dosing, possibly reflecting …

Rheumatoid arthritis is characterised by pain, swelling, and destruction of joints, with
resultant disability. Only disease-modifying antirheumatic drugs can interfere with the …

Background Since initial approval for the treatment of rheumatoid arthritis (RA), rituximab
has been evaluated in clinical trials involving various populations with RA. Information has …

Background and objective In patients with severe interstitial lung disease (ILD) progressing
despite conventional immunosuppression, rituximab, a B‐lymphocyte depleting monoclonal …